A $948.8M Fraud Verdict Became a $440M Bankruptcy Settlement

In April 2025, a federal jury found that Omnicare -- described in DOJ's 2019 complaint⧉ as the country's largest long-term care pharmacy, then operating about 160 pharmacies in 47 states -- had billed Medicare, Medicaid, and TRICARE for 3.34 million false claims filed from 2010 to 2018.▸ Ten weeks later, Judge Colleen McMahon⧉ put a final number on it under the False Claims Act -- the law that lets the government treble its actual damages and add a civil penalty on top when a company defrauds a federal program: $948.8 million. What that judgment has actually turned out to be worth is a different question, and the answer came not from the trial court but from a bankruptcy court a year later.

The mechanism, per DOJ's complaint: instead of getting a doctor to reauthorize a prescription once it expired or ran out of refills, Omnicare staff assigned the same expired prescription a new claim number and kept dispensing -- a practice the company internally called a 'rollover' -- sometimes for months or years, to elderly and disabled residents of assisted living and other long-term care facilities.

The jury's own number was comparatively modest: $135.6 million in actual damages⧉ -- an average of roughly $40.58 in improper payment per false claim, spread across 3,341,032 of them, not a handful of large fraudulent bills.▸ The False Claims Act automatically triples that figure, adding $271.2 million. On top of the trebled total, Judge McMahon added a $542 million civil penalty against Omnicare, and held CVS Health jointly and severally liable for $164.8 million of that penalty -- 30.4% of it, matching the 30.4% share of false claims the jury found CVS had caused after it acquired Omnicare in August 2015. Trebled damages plus penalty is where $948.8 million comes from.

That penalty itself was already a discount.▸ Applied literally, the FCA's inflation-adjusted per-claim penalty schedule -- $5,500 to $11,000 per claim filed before November 2015, $13,946 to $27,894 per claim after -- would have put Omnicare's minimum exposure at roughly $26.9 billion, by the defendants' own estimate, which the court's opinion doesn't dispute as a ceiling calculation. The government never sought that; it asked for $542 million, a 4-to-1 ratio of penalty to actual damages, and the court agreed that a fine of 'the serious, but not the surreal' scale like that one survives the Constitution's excessive-fines test where a literal $26.9 billion would not. Put another way: the $542 million the court called appropriate is about 2% of the floor the statute's own math would otherwise require.

Omnicare didn't pay $948.8 million.▸ Eleven weeks after the penalty ruling, on September 22, 2025, it filed for Chapter 11 bankruptcy⧉ in the Northern District of Texas, naming the litigation as the reason and lining up $110 million in debtor-in-possession financing -- borrowed money a bankrupt company is allowed to raise, secured ahead of its other creditors, to keep operating during the case. Omnicare's president, David Azzolina, disputed the underlying case in the same filing, calling it 'a civil lawsuit alleging technical violations of pharmacy law based on practices the government knew about and approved' with 'no allegations of harm to any Omnicare patients,' and the penalty 'extreme and, we believe, unconstitutional.' That is Omnicare's own characterization; it sits alongside a jury's finding of 3.34 million false claims and a federal complaint naming specific drug classes -- antipsychotics, anticonvulsants, antidepressants -- dispensed on expired authority to residents who depended on someone else managing their care.

Bankruptcy changes what a judgment is worth, because a bankrupt company's assets get divided among everyone it owes, not paid out in full to whoever won first.▸ In a July 1, 2026 bankruptcy-court filing, Omnicare and CVS Health agreed to pay the government $440 million -- roughly 46 cents on every dollar of the $948.8 million judgment -- conditioned on the separate, court-approved sale of Omnicare's business to GenieRx Holdings closing. The bankruptcy court approved that sale on May 13, 2026⧉; Omnicare's own announcement of it describes the company's ongoing work supporting 'residents in skilled nursing and assisted living settings' -- the same population the 2019 complaint said it had put at risk.

The settlement isn't final.▸ A bankruptcy-court hearing on it is scheduled for August 12, 2026. If approved, $130 million is due within 14 days of the agreement taking effect -- about 30% of the total. The remaining $310 million isn't due until March 15, 2028, with CVS Health standing behind that balance if Omnicare's bankruptcy estate hasn't paid it by March 31, 2028. That's a payment schedule stretching nearly two years past the settlement itself, on a judgment that took a jury one afternoon to calculate and a judge ten weeks to finalize.